http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0518621-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae84948901b77f34fd51c41264d8d19c
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-58
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-58
filingDate 2005-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3a4a8c06b0135392be6f6cb0075a0e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77a9cd68e12424e1f833f458574206a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b6161d6bff7542a3d13196a7f65dd14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edb4694bf845f51757da453f29918ea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37ef58fc92fe3c7579b45bca87f63d45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7ad598cc34c644280c02b8653520aeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04cf154d727337725749883e1554bb33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f11f18731838b9ec1776afed2ccdcb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccc7703060955fd59d9aa4615795dab6
publicationDate 2008-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-PI0518621-A2
titleOfInvention compounds, pharmaceutical composition, method of preparing a composition, and use of a compound
abstract COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING A COMPOSITION, AND USE OF A COMPOUND. The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action inhibiting serotonin resorption and partial agonism at dopamine D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament which gives a beneficial effect. The compounds have the general formula (1): wherein the symbols have the meanings given in the specification and their tautomers, stereoisomers and N-oxides, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and their tautomers, stereoisomers and N-oxides.
priorityDate 2004-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5202
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7096
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549034
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414939035

Total number of triples: 25.